Xoma Royalty's 12 Months dividend pay out ratio, the ratio that measures the proportion of earnings, that Xoma Royalty' distributes to its shareholders in the form of dividends, sequentially decreased to 22.95% in the first quarter 2026, this result is above Xoma Royalty's average of of 37.25%.

Within Healthcare sector 35 other companies have achieved higher 12 Months dividend pay out ratio. While in terms of ranking among all other companies, the company has moved form 915 in the fourth quarter 2025, to 927.

Dividend in Glossary

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

Back to XOMA Dividend Comparisons >> See also XOMA's dividend growth by quarter >> See also XOMA's eps growth

Cumulative Dividend Pay out Ratio	I. Quarter (Mar 31 2026)	IV. Quarter (Dec 31 2025)	III. Quarter (Sep 30 2025)	II. Quarter (Jun 30 2025)	I. Quarter (Mar 31 2025)
XOMA's Pay out Ratio (TTM)	22.95 %	24.42 %	-	-15.22 %	-19.78 %
XOMA's Dividend Pay out Ratio Total Ranking	# 927	# 915	# 877	# 0	# 0

News about Xoma Royalty Corporation Dividends

Defying Odds: XOMA's Resilience Shines Through with Dividend Declaration

In a recent press release by XOMA Corporation (XOMA), the San Francisco-based biotech company reaffirmed its dedication to its valued shareholders amidst the backdrop of a challenging stock performance. The press release declared the upcoming quarterly dividend payment to XOMAP and XOMAO stockholders, offering a beacon of hope and stability to stakeholders during these uncertain times. This article will delve into XOMA's resilience and commitment to its investors and explore the implications of the dividend announcement.
XOMA's Steadfast Commitment to Shareholders
Despite the turbulent stock market conditions and ever-evolving challenges faced by businesses worldwide, XOMA has demonstrated an unwavering commitment to its shareholders. By declaring dividends for the first quarter and announcing upcoming payments to those who held XOMAP and XOMAO stocks as of January 3, 2024, the company has reinforced their dedication to providing stable returns to investors. This decision reflects XOMA's confidence in its long-term growth potential and a strong belief in the fundamental value of the company.

XOMA's Commitment to Shareholders: Declares Dividends Amidst a Challenging Stock Performance

XOMA Corporation, a biotechnology company based in Emeryville, California, announced today that their Board of Directors has approved cash dividends for holders of XOMA's Series A and Series B Cumulative Preferred Stock. This news comes amidst a troubled period for XOMA's stock performance, with a decline of -3.75% over the past week and a YTD performance of -16.08%. However, there is a ray of hope as the stock is currently trading 14.5% above its 52-week low.
The declaration of quarterly preferred stock dividends by XOMA is a positive move for the company and its shareholders. Dividends are a way for companies to distribute profits to their stockholders, creating an additional incentive for investors to hold onto their shares. By authorizing these cash dividends, XOMA is demonstrating its commitment to rewarding its investors and maintaining a strong relationship with them.

XOMA's Dividend Pay out Ratio Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 12
Healthcare Sector	# 36
S&P 500	# 927

Dividend Pay out Ratio Statistics
High	Average	Low
79.15 %	37.25 %	7.33 %
(Sep 30 2022)		(Jun 30 2021)

Other Dividend Ratios
Highest Ranking Dividend Yield
Lowest Ranking Dividend Yield
Annual Dividend Pay out for XOMA
XOMA's Dividend Yield

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.